Rebalix
Logo AmundiAmundi · sheet of 10 September 2026
ETF sheet · official issuer and register data

Amundi S&P World Health Care Screened UCITS ETF Acc

WELS · IE0006FM6MI8 · class UCITS ETF Acc · EUR · domicile Ireland
Equity · Global · Health care · Sustainable / ESGSFDR art. 8
Index tracked: S&P World Health Care Weighted & Screened Index
TER
0.18%+ trans. 0.07%
Fund size
564 m EUR
Tracking difference
+0.06%3-year avg
🇮🇹 tax rate
26.00%white list 0.00%
Replication
Physical
Income
Accumulating
Launch 20 Sept 2022 · costs from the KID as of 2 Sept 2026 · 85 securities held · 9 venues (ESMA register)

The fund’s objective — in the issuer’s words

From the Key Information Document (KID) · 4 Aug 2026
The Sub-Fund is passively managed. The objective of the Sub-Fund is to track the performance of the S&P World Health Care Weighted & Screened Index (the "Index"). The anticipated level of the tracking error, under normal market conditions, is indicated in the prospectus of the Sub-Fund. The Sub-Fund promotes environmental and/or social characteristics through among others, replicating an Index integrating an environmental, social and governance ("ESG") rating. The Index is an equity index that measures the performance of eligible equity securities from…

Performance since series start (in euro) — base 100

20 Sept 20228 Sept 2026 · dividends reinvested where declared by the issuer
202320242025202612496116
High 124 (30 Aug 2024) · low 96 (10 Mar 2023) · last 116. Past performance is not indicative of future results.

Returns in euro

1 year+13.7%
3 years+12.5%
5 yearsseries too young
10 yearsseries too young
Since series start+16.3%

Risk · 1 / 3 / 5 years

Volatility (ann.)15.16%13.59%
Max drawdown−12.11%−22.58%
Sharpe0.780.12
Sortino1.240.17
Sharpe/Sortino: risk-free = ECB MRO avg; nominal volatility
Rebalix · WELS · IE0006FM6MI81
RebalixWELS · IE0006FM6MI8 · sheet of 10 September 2026

Tracking difference — year by year

Fund minus index, complete calendar years · from issuer-declared series
YearFundIndexTD
2025+0.31%+0.24%+0.08%
2024+7.83%+7.76%+0.07%
2023+2.15%+2.11%+0.04%

Holdings

Portfolio as declared by the issuer · 1 Sept 2026 · 85 securities · top-10 weight = 52.6%
Top holdingsWeight
ELI LILLY & CO11.4%
ABBVIE INC8.1%
MERCK & CO. INC.5.5%
NOVARTIS AG-REG4.9%
UNITEDHEALTH GROUP INC4.6%
ASTRAZENECA GBP4.2%
AMGEN INC4.0%
ROCHE HOLDING AG - GENUSSS CHF3.7%
GILEAD SCIENCES INC3.4%
THERMO FISHER SCIENTIFIC INC2.8%
Countries (% of fund)
United States73.8%Switzerland10.1%United Kingdom5.4%Denmark2.7%Japan2.6%
Sectors (% of fund)
Health Care100.0%

Listing venues

ESMA register (FIRDS) and official exchange lists
· Börse Düsseldorf, Börse Frankfurt, Börse Hamburg, Börse Hannover, Börse München / gettex, Börse Stuttgart, Tradegate Exchange
GLHL · Euronext Paris
WEL9 · Xetra (Deutsche Börse)
+ 16 unmapped venues (MTF, RFQ, professional)

Official documents

Clickable links in the PDF
KID · www.amundietf.it/pdfDocuments/kid-priips/IE0006FM6MI8/ENG/NLD
Factsheet · www.amundietf.it/pdfDocuments/monthly-factsheet/IE0006FM6MI8/ENG/FRA/I
Prospectus · www.amundietf.it/pdfDocuments/prospectus/IE0006FM6MI8/ENG/GBR
The live sheet, always up to date
rebalix.com/en/etf/IE0006FM6MI8
Series, distributions, holdings and documents refresh daily.
Sheet produced on 10 September 2026 · data as of the dates shown section by section. Sources: official issuer documents (KID, factsheet, NAV series, declared portfolio), ESMA register (FIRDS), European Central Bank (FX), Italian tax authority / issuer (white-list share). Public methodology: rebalix.com/en/methodology. “—” = not published by the source, never estimated.

Informational document generated by rebalix.com: facts only, no recommendations. Not investment advice or investment research under Directive 2014/65/EU (MiFID II), nor an offer or solicitation. Past performance is not indicative of, nor a guarantee of, future results; the value of an investment can go down as well as up. Before any decision read the issuer’s KID and Prospectus; tax treatment depends on individual circumstances. Trademarks and logos belong to their respective owners and only identify the instrument and its issuer: no affiliation, sponsorship or endorsement.

Rebalix · WELS · IE0006FM6MI82